Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ILK | Q13418 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 3/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174621 | 0.81 | MPO (0.47) | EGFRAPPALDH1A1HSD17B10 | |
| SCHEMBL23264581 | 0.81 | KDR (0.54) | GRM4KDRMAOADYRK1AILK | |
| SCHEMBL9616706 | 0.78 | MIF (0.45) | GRM4KDRCHEK1CHEK2MIF | |
| SCHEMBL5256515 | 0.75 | MAOA (0.48) | GRM4KDRMAOADYRK1AMIF | |
| SCHEMBL27248610 | 0.75 | ALDH1A1 (0.46) | FGFR1ALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL20589705 | 0.74 | KMT2A (0.42) | MAOAFGFR1ALDH1A1HSD17B10 | |
| SCHEMBL29880457 | 0.74 | KMT2A (0.42) | MAOAFGFR1ALDH1A1HSD17B10 | |
| SCHEMBL16537752 | 0.72 | MIF (0.43) | CHEK2MIFSLC22A12APPALDH1A1 | |
| SCHEMBL1012140 | 0.72 | FBP1 (0.53) | GRM4KDRILKEGFRFGFR1 | |
| SCHEMBL21707866 | 0.71 | HSD17B10 (0.54) | ALDH1A1CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | GRM4 4708/4885KDR 1670/4885CHEK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.